Company intelligence / Profile preview

Nuvothera

Ownership: Private
Development stage: Commercial

Overview

Nuvothera has commercialized two main product lines—a super-micronized turmeric curcumin supplement for joint health and inflammation, and Prosoria, an over-the-counter topical system for psoriasis. The company claims improved bioavailability for its turmeric product and clinical-strength efficacy for its skin treatments. No formal clinical trial data or regulatory drug approvals are reported; all claims are based on consumer use and in vitro testing.

Therapeutic areas: DermatologyRheumatologyInfectious Diseases
Modalities: Small molecule (turmeric curcumin supplement)Non-pharmacological therapy (topical OTC treatments)Botanical extract (turmeric/curcumin-based products)
Industry: Food & Nutrition

Drug pipeline

2 assets

Prosoria

Commercial

Indications: Psoriasis

1 more asset in the full pipeline.

Partnerships

TechFW technology incubator/accelerator partnership

Beyond the preview

Go deeper on Nuvothera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuvothera.